LPCN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lipocine Inc (LPCN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of recent positive news, weak financial performance, and neutral technical indicators suggest that waiting for more favorable conditions or clearer catalysts would be prudent.
The MACD is below 0 and negatively contracting, RSI is neutral at 42.015, and moving averages are converging. The stock is trading near its S2 support level of 6.606, indicating limited upward momentum in the pre-market.
Analysts have raised price targets significantly, citing a higher probability of approval for LPCN 1154 and favorable safety data. The LPCN 1154 post-partum depression trial is on track for a readout in early April.
The company's financial performance in Q4 2025 was poor, with revenue, net income, and EPS all showing significant declines. Additionally, there are no recent news updates or significant insider or hedge fund activity to suggest strong near-term momentum.
In Q4 2025, revenue dropped by -67.19% YoY, net income declined by -232.99% YoY, and EPS fell by -235.48% YoY. Gross margin remained stable at 100%. Overall, the financials indicate a struggling company.
Analysts have raised price targets significantly (Alliance Global to $11 and H.C. Wainwright to $15) and maintain a Buy rating, citing favorable safety data and higher approval probability for LPCN 1154.
